AstraZeneca Pharmaceuticals LP has launched separate patent infringement actions against nine rival drugmakers—including Apotex Corp., Mylan Pharmaceuticals Inc., and Teva Pharmaceuticals USA Inc.—seeking to block their attempts to release a generic version of blockbuster cholesterol drug Crestor®. The complaints accuse the nine companies of infringing patents in their submission of abbreviated new drug applications to the U.S. FDA. The plaintiffs (AstraZeneca and IPR Pharmaceuticals Inc.) seek a judgment that their patents are valid, enforceable, and infringed by each defendant, as well as orders stipulating that the effective date of any FDA approval of the generic tablets should not be earlier than the expiration dates of the asserted patents and enjoining the defendants from selling the drug prior to this date. AstraZeneca is represented in this matter by Finnegan.
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Press Release
Finnegan Earns Law360’s Practice Group of the Year for Intellectual Property
January 18, 2023
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.